Simponi, Simponi Aria (Golimumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The simponi, simponi aria (golimumab) market size has grown rapidly in recent years. It will grow from $22.16 billion in 2025 to $24.38 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to clinical success of tnf inhibitors, rising autoimmune disease prevalence, limitations of conventional dmards, strong rheumatologist adoption, regulatory approvals across indications.

The simponi, simponi aria (golimumab) market size is expected to see strong growth in the next few years. It will grow to $35.3 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to growth in autoimmune patient population, increasing biologic reimbursement coverage, expansion of infusion centers, biosimilar competition awareness, demand for sustained efficacy therapies. Major trends in the forecast period include sustained use of tnf alpha inhibitors, growing adoption of biologics in autoimmune diseases, expansion of infusion based biologic therapies, increased focus on long term disease control, rising patient preference for less frequent dosing.

The rising prevalence of autoimmune diseases is expected to drive the growth of the simponi and simponi aria (golimumab) market. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues, perceiving them as foreign. Cases of rheumatoid arthritis are increasing due to a combination of genetic, environmental, and lifestyle factors. Simponi and Simponi Aria (golimumab) are effective biologic therapies that address the growing burden of autoimmune diseases, providing targeted treatment for conditions such as rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based national charity, reported that the number of people living with cystic fibrosis in the UK rose from 11,148 in 2022 to 11,318 in 2023. Therefore, the increasing prevalence of autoimmune diseases is supporting the growth of the simponi and simponi aria (golimumab) market.

Key companies in the simponi and simponi aria (golimumab) market are focusing on developing cost-effective alternatives to Simponi (golimumab) and improving patient access to biologic therapies for autoimmune diseases in the EU and UK. Golimumab biosimilars are biologic drugs that closely resemble the original Simponi, offering comparable safety and efficacy at potentially lower costs. For instance, in May 2024, Bio-Thera Solutions, Ltd., a China-based biopharmaceutical company, partnered with STADA Arzneimittel AG, a Germany-based pharmaceutical company, in an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi (golimumab). Under the agreement, Bio-Thera will handle development, manufacturing, and supply of BAT2506, while STADA will have exclusive commercialization rights in the EU, UK, Switzerland, and selected other countries. This collaboration aims to provide an affordable, high-quality alternative to Simponi for treating autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis, with potential milestone payments included, highlighting the strategic focus on expanding access to biologic therapies in immunology.

In May 2023, Alvotech, an Iceland-based biotechnology company, announced a partnership with Advanz Pharma. This collaboration aims to enhance patient access to more affordable biologics by combining Alvotech’s expertise in development and commercial supply with Advanz Pharma’s capabilities in registration and commercialization within the European market. Advanz Pharma, a UK-based biotechnology manufacturing company, is involved in the development of biologics including Simponi.

Major companies operating in the simponi, simponi aria (golimumab) market are Merck & Co. Inc., Johnson & Johnson.

North America was the largest region in the simponi, simponi aria (golimumab) market in 2025. The regions covered in the simponi, simponi aria (golimumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the simponi, simponi aria (golimumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the simponi market by increasing costs associated with monoclonal antibody manufacturing inputs, infusion packaging materials, and cold chain transportation. These impacts are more pronounced in regions dependent on imported biologics such as asia pacific and eastern europe. Hospital and clinic acquisition costs have risen, affecting treatment budgets. However, tariffs have encouraged regional biologics manufacturing investments. This improves long term supply security and supports broader biologic access.

The simponi, simponi aria (golimumab) market research report is one of a series of new reports that provides simponi, simponi aria (golimumab) market statistics, including simponi, simponi aria (golimumab) industry global market size, regional shares, competitors with a simponi, simponi aria (golimumab) market share, detailed simponi, simponi aria (golimumab) market segments, market trends and opportunities, and any further data you may need to thrive in the simponi, simponi aria (golimumab) industry. This simponi, simponi aria (golimumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Simponi and Simponi Aria (Golimumab) are biologic therapies that inhibit tumor necrosis factor-alpha (TNF-alpha) to control inflammation in autoimmune disorders. They are indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

The main forms of Simponi and Simponi Aria (Golimumab) include type I, type II, type III, and type IV. These medications are administered via subcutaneous injection or intravenous infusion. Their primary clinical applications are rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, and they are predominantly used in hospital and clinic settings.

The simponi and simponi aria (golimumab) market consists of sales of syringes, autoinjectors, and intravenous infusion formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.